Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,687
  • Shares Outstanding, K 69,438
  • Annual Sales, $ 70 K
  • Annual Income, $ -84,950 K
  • EBIT $ -87 M
  • EBITDA $ -84 M
  • 60-Month Beta 1.70
  • Price/Sales 1,132.37
  • Price/Cash Flow N/A
  • Price/Book 2.94

Options Overview Details

View History
  • Implied Volatility 197.21% (+8.93%)
  • Historical Volatility 130.46%
  • IV Percentile 44%
  • IV Rank 15.59%
  • IV High 908.26% on 08/07/25
  • IV Low 65.86% on 05/05/25
  • Expected Move (DTE 2) 0.1615 (14.55%)
  • Put/Call Vol Ratio 2.74
  • Today's Volume 936
  • Volume Avg (30-Day) 2,118
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 31,985
  • Open Int (30-Day) 20,109
  • Expected Range 0.9485 to 1.2715

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 2
  • High Estimate $-0.29
  • Low Estimate $-0.31
  • Prior Year $-0.51
  • Growth Rate Est. (year over year) +41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +7.77%
on 04/10/26
1.7850 -37.82%
on 03/31/26
-0.5500 (-33.13%)
since 03/13/26
3-Month
1.0300 +7.77%
on 04/10/26
2.0300 -45.32%
on 02/24/26
-0.5300 (-32.32%)
since 01/14/26
52-Week
1.0300 +7.77%
on 04/10/26
2.9789 -62.74%
on 09/09/25
-0.6600 (-37.29%)
since 04/14/25

Most Recent Stories

More News
Inovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December...

INO : 1.1100 (+1.83%)
INO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses in Inovio to Contact Him Directly to Discuss Their Options...

INO : 1.1100 (+1.83%)
INO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Inovio Pharmaceuticals, Inc. Securities Lawsuit -- The Gross Law Firm

NEW YORK , April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).

INO : 1.1100 (+1.83%)
Deadline Soon: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming  April 7, 2026  deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed...

INO : 1.1100 (+1.83%)
Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO

LOS ANGELES , April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or "the Company") (NASDAQ: INO ) for...

INO : 1.1100 (+1.83%)
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , April 6, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc....

INO : 1.1100 (+1.83%)
INO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options

INO : 1.1100 (+1.83%)
INO Deadline: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , April 2, 2026 /PRNewswire/ --

INO : 1.1100 (+1.83%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) and certain...

INO : 1.1100 (+1.83%)
INOVIO Announces Pricing of $17.5 Million Public Offering

PLYMOUTH MEETING, Pa. , April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...

INO : 1.1100 (+1.83%)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 1.1633
2nd Resistance Point 1.1467
1st Resistance Point 1.1283
Last Price 1.1100
1st Support Level 1.0933
2nd Support Level 1.0767
3rd Support Level 1.0583

See More

52-Week High 2.9789
Fibonacci 61.8% 2.2344
Fibonacci 50% 2.0044
Fibonacci 38.2% 1.7745
Last Price 1.1100
52-Week Low 1.0300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.